pirbuterol and Lung Diseases, Obstructive
pirbuterol has been researched along with Lung Diseases, Obstructive in 9 studies
pirbuterol: structure
Lung Diseases, Obstructive: Any disorder marked by obstruction of conducting airways of the lung. AIRWAY OBSTRUCTION may be acute, chronic, intermittent, or persistent.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pirbuterol in a lower dosage (15 mg by mouth) in six further patients with hypoxic chronic bronchitis and emphysema produced similar changes in total pulmonary vascular resistance and right ventricular ejection fraction." | 5.27 | Effects of pirbuterol and sodium nitroprusside on pulmonary haemodynamics in hypoxic cor pulmonale. ( Flenley, DC; Hannan, WJ; MacNee, W; Muir, AL; Wathen, CG, 1983) |
| " Our conclusion is that pirbuterol is at least as effective and safe under conditions of chronic administration to asthmatics as metaproterenol and therefore can be considered a suitable alternative for therapy." | 2.67 | Comparison of safety and efficacy of inhaled pirbuterol with metaproterenol. ( Brandon, ML; Grieco, M; Hudson, L; Rosenthal, RR; Spector, SL; Tashkin, D; Tinkelman, DG; Votteri, B, 1990) |
| "Pirbuterol is a beta-adrenoceptor agonist which differs structurally from salbutamol in the substitution of a pyridine ring for the benzene ring." | 2.37 | Pirbuterol. A preliminary review of its pharmacological properties and therapeutic efficacy in reversible bronchospastic disease. ( Brogden, RN; Richards, DM, 1985) |
| "Pirbuterol in a lower dosage (15 mg by mouth) in six further patients with hypoxic chronic bronchitis and emphysema produced similar changes in total pulmonary vascular resistance and right ventricular ejection fraction." | 1.27 | Effects of pirbuterol and sodium nitroprusside on pulmonary haemodynamics in hypoxic cor pulmonale. ( Flenley, DC; Hannan, WJ; MacNee, W; Muir, AL; Wathen, CG, 1983) |
| " The characteristics of the oral route are easy usage, precise dosage and assured effects." | 1.27 | Oral beta 2-selective adrenergic bronchodilators. ( Daniotti, S; Dottorini, M; Grassi, V; Schiassi, M; Tantucci, C, 1986) |
Research
Studies (9)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (55.56) | 18.7374 |
| 1990's | 4 (44.44) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| MacNee, W | 1 |
| Wathen, CG | 1 |
| Hannan, WJ | 1 |
| Flenley, DC | 1 |
| Muir, AL | 1 |
| Ashutosh, K | 1 |
| Dev, G | 1 |
| Steele, D | 1 |
| Holten, K | 1 |
| Lulling, J | 1 |
| Schaaning, J | 1 |
| Vander Straeten, M | 1 |
| Verstraeten, JM | 1 |
| Hoffarth, HP | 1 |
| Freyberger, H | 1 |
| Völkl, KP | 1 |
| Ulmer, WT | 1 |
| Tinkelman, DG | 1 |
| Brandon, ML | 1 |
| Grieco, M | 1 |
| Hudson, L | 1 |
| Rosenthal, RR | 1 |
| Spector, SL | 1 |
| Tashkin, D | 1 |
| Votteri, B | 1 |
| Neilly, JB | 1 |
| Carter, R | 1 |
| Tweddel, A | 1 |
| Martin, W | 1 |
| Hutton, I | 1 |
| Banham, SW | 1 |
| Stevenson, RD | 1 |
| Richards, DM | 1 |
| Brogden, RN | 1 |
| Grassi, V | 1 |
| Daniotti, S | 1 |
| Schiassi, M | 1 |
| Dottorini, M | 1 |
| Tantucci, C | 1 |
| Raimondi, G | 1 |
| Rodriguez-Moncalvo, JJ | 1 |
Reviews
1 review available for pirbuterol and Lung Diseases, Obstructive
| Article | Year |
|---|---|
Pirbuterol. A preliminary review of its pharmacological properties and therapeutic efficacy in reversible bronchospastic disease.
Topics: Adrenergic beta-Agonists; Animals; Asthma; Biotransformation; Bronchial Spasm; Bronchodilator Agents | 1985 |
Trials
5 trials available for pirbuterol and Lung Diseases, Obstructive
| Article | Year |
|---|---|
Nonbronchodilator effects of pirbuterol and ipratropium in chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Aged; Bronchi; Bronchodilator Agents; Double-Blind Method; Ethanolamines | 1995 |
The use of two inhaled beta agonists for the treatment of COPD: a summary of European data.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Ethanolamines; Europe; Humans; Lung | 1993 |
[Inhalation therapy with selective beta 2-sympathomimetic drugs. Effect of pirbuterol administered via the Autohaler and salbutamol administered via the Diskhaler in obstructive respiratory tract disease].
Topics: Adult; Aerosols; Aged; Airway Resistance; Albuterol; Bronchodilator Agents; Ethanolamines; Female; H | 1990 |
Comparison of safety and efficacy of inhaled pirbuterol with metaproterenol.
Topics: Administration, Inhalation; Adolescent; Adult; Aerosols; Aged; Asthma; Bronchodilator Agents; Double | 1990 |
Long term haemodynamic, pulmonary function and symptomatic effects of pirbuterol in COPD.
Topics: Aged; Blood Gas Analysis; Bronchodilator Agents; Carbon Dioxide; Ethanolamines; Female; Hemodynamics | 1989 |
Other Studies
3 other studies available for pirbuterol and Lung Diseases, Obstructive
| Article | Year |
|---|---|
Effects of pirbuterol and sodium nitroprusside on pulmonary haemodynamics in hypoxic cor pulmonale.
Topics: Adrenergic beta-Agonists; Adult; Aged; Ethanolamines; Female; Ferricyanides; Hemodynamics; Humans; H | 1983 |
Oral beta 2-selective adrenergic bronchodilators.
Topics: Administration, Oral; Adrenergic beta-Agonists; Aged; Asthma; Bronchodilator Agents; Child; Clenbute | 1986 |
Effects of beta-adrenergic agents on hypokalemia.
Topics: Adrenergic beta-Agonists; Ethanolamines; Humans; Hypokalemia; Lung Diseases, Obstructive; Potassium | 1987 |